Although limited numbers of patients have been tested, it seems that activating mutations in the KRAS oncogene are observed in approximately 40% of SBA patients, which is similar to the rate observed in colorectal cancer (Bamford et al, 2004). Here, KRAS is linked to colorectal cancer.